Skip to main content
. 2022 Jan 10;9(1):ofab593. doi: 10.1093/ofid/ofab593

Table 5.

Morbidity and Mortality Risks of Aspergillosis in At-Risk Patients (Healthcare Cost and Utilization Project, 2018), United States

Diagnosis Average Cost of Visit
(in $1000)
Average Length of Stay (Days) Infection, No., Rate per 100 000 Deaths, No., % Infected Relative Risk of Mortality (95% CI) Population, No.
+ Ratio + Ratio
All visits with at-risk diagnoses 30.43 101.02 3.41 5.53 13.40 2.59 12 030
67.53
1240
10.31
3.19 (3.03–3.36) 17 813 520
Cancer 77.68 307.23 3.96 6.00 17.96 2.99 3190
114.56
715
22.41
2.91 (2.72–3.11) 2 784 530
 Leukemia 108.71 373.40 3.43 8.06 22.34 2.77 2205
823.08
285
12.93
2.46 (2.21–2.74) 267 895
 Lung, trachea, bronchus 69.18 146.82 2.12 6.00 9.86 1.64 670
169.77
110
16.42
1.90 (1.60–2.25) 394 645
 Non-Hodgkin lymphoma 89.38 364.86 4.08 6.54 18.87 2.89 555
278.80
115
20.72
4.43 (3.75–5.20) 199 065
Cystic fibrosis 51.40 69.38 1.35 9.39 12.11 1.29 1800
5939.61
20
1.11
1.05 (.67–1.63) 282 645
Influenza 55.59 275.87 4.96 5.43 17.18 3.16 575
152.14
85
14.78
4.23 (3.46–5.13) 377 950
Transplant history 35.42 113.04 3.19 5.41 14.56 2.69 1170
444.65
135
11.54
4.82 (4.10–5.63) 282 645
 Bone marrow 48.39 72.19 1.49 6.83 11.97 1.75 170
781.25
40
23.53
5.80 (4.35–7.57) 1005
 Kidney 29.06 120.19 4.14 4.90 12.95 2.64 190
159.80
20
10.53
5.54 (3.63–8.27) 118 895
 Lung 36.82 63.47 1.72 5.94 14.56 2.69 205
1851.02
a 1.06 (.45–2.44) 11 075
 Stem cell 54.29 153.34 2.83 6.85 17.64 2.57 390
1015.76
60
15.38
3.49 (2.74–4.40) 38 395
Transplant complications 68.62 206.00 3.00 8.39 21.91 2.61 1350
1046.07
205
15.19
4.34 (3.81–4.94) 142 875
 Bone marrow 98.91 321.76 3.25 11.88 36.85 3.10 65
2260.87
a 2.76 (1.51–4.77) 2900
 Kidney 47.33 119.94 2.53 7.01 16.11 2.30 225
285.88
40
17.78
6.97 (5.21–9.17) 85 650
 Lung 112.28 144.78 1.72 8.75 16.39 1.87 590
6190.98
65
11.02
2.37 (1.85–3.02) 11 325
 Stem cell 133.45 303.81 2.28 16.67 29.26 1.75 325
3296.15
70
21.54
2.42 (1.94–2.98) 9860

Abbreviation: CI, confidence interval.

Estimates suppressed with Healthcare Cost and Utilization Project protocols.